ArticleCancers2021
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST).
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Molecular profiling and access to treatment for rare cancers in Europe.Nature communications · 2026Article
- The Morphologic Spectrum of Mediastinal Yolk Sac Tumors: Diagnostic Challenges and Pitfalls.Cancers · 2026Review
- Genetics of High-Grade Endometrioid Adenocarcinoma of the Ovary With Yolk Sac Differentiation: A Case Report.Cureus · 2025Article
- Treatment of recurrent ovarian germ cell tumours: Is there a role for immune checkpoint inhibitors?Gynecologic oncology reports · 2024Review
- Maediastinal germ cell tumors: analysis using hospital-based cancer registry data in Japan.International journal of clinical oncology · 2024Article
- Pure yolk sac ovarian tumor in a young female-Case report with brief review of literature.SAGE open medical case reports · 2024Article
- Ovarian yolk sac tumor in a premenarchal girl.Wiener medizinische Wochenschrift (1946) · 2023Article
- Pregnancy and Delivery After Ovarian Yolk Sac Tumor: A Case Report.The American journal of case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with malignant ovarian germ cell tumors (MOGTCs) have a very good prognosis and chemotherapy provides curative treatment; however, patients with yolk sac tumors (OYSTs) have a significantly worse prognosis. OYSTs are rare tumors and promising results are expected with the use of specific therapeutic strategies after the failure of platinum-based first-line and salvage regimens. We initiated a project in collaboration with EORTC SPECTA, to explore the molecular characteristics of OYSTs. The pilot project used retrospective samples from ten OYST relapsed and disease-free patients. Each patient had a molecular analysis performed with FoundationOne CDx describing the following variables according to the Foundation Medicine Incorporation (FMI): alteration type (SNV, deletion), actionable gene alteration, therapies approved in EU (for patient's tumor type and other tumor types), tumor mutational burden (TMB), and microsatellite instability (MSI) status. A total of 10 patients with OYST diagnosed between 2007 and 2017 had a molecular analysis. A molecular alteration was identified in four patients (40%). A subset of three patients (33.3% of all patients) harbored targetable oncogenic mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.